MarketPeel
Insider Trading Intelligence
Pricing
…
RD

Richard Douglas

MXCT
DIRECTOR · MAXCYTE, INC. · CIK 0001021015
FILING MIX · LIFETIME88%/12%
BUYS
57
SELLS
8
TOTAL VALUE
$1.41M
COMPANIES
3
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
263,321
AVG SELL PX
—
TRADE KIND
SHOWING 65 / 65
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 5 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Richard Douglas, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+80.00%+2.79%-1.77%+4.56%+2.78%—
14d5+60.00%+10.66%+1.84%+8.82%+1.18%—
30d5+60.00%+20.28%+6.02%+14.27%+3.13%—
60d5+40.00%+27.49%+6.81%+20.68%-11.91%—
90d5+60.00%+33.21%+10.14%+23.08%-8.63%—
180d5(1 pending)+25.00%+50.72%+10.17%+40.54%-37.91%—
1y5(2 pending)+33.33%+191.83%+29.07%+162.76%-29.18%—
2y5(2 pending)+33.33%+20.79%+43.36%-22.57%-57.90%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
MXCT · 260,998 shares · as of Jun 17, 2026
065,250130,499195,749260,99820222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 57 buys / 8 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
NVAX
NOVAVAX INC
PURCHASE
18,880——73,220Jun 20, 2026Jun 23, 2026 ↗View →
NVAX
NOVAVAX INC
SALE
18,880——0Jun 20, 2026Jun 23, 2026 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
21,270——21,270Jun 18, 2026Jun 23, 2026 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
14,180——14,180Jun 18, 2026Jun 23, 2026 ↗View →
MXCT
MAXCYTE, INC.
PURCHASEGRANT
Stock grant
49,579——49,579Jun 17, 2026Jun 22, 2026 ↗View →
MXCT
MAXCYTE, INC.
PURCHASEGRANT
Stock grant
30,421——260,998Jun 17, 2026Jun 22, 2026 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,909——19,909Jun 9, 2026Jun 11, 2026 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,000——70,000Jun 9, 2026Jun 11, 2026 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,323——2,323Jun 9, 2026Jun 11, 2026 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASE
70,000$1.40$98.0K195,000Mar 19, 2026Mar 20, 2026 ↗View →
MXCT
MAXCYTE, INC.
PURCHASE
80,000$1.39$111.0K230,577Aug 13, 2025Aug 13, 2025 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
28,326$6.42$181.9K28,326Jun 20, 2025Jun 24, 2025 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
18,884——18,884Jun 20, 2025Jun 24, 2025 ↗View →
MXCT
MAXCYTE, INC.
PURCHASEGRANT
Stock grant
50,790——50,790Jun 18, 2025Jun 23, 2025 ↗View →
MXCT
MAXCYTE, INC.
PURCHASEGRANT
Stock grant
29,210——150,577Jun 18, 2025Jun 23, 2025 ↗View →
NVAX
NOVAVAX INC
PURCHASE
10,420——54,340Jun 12, 2025Jun 13, 2025 ↗View →
NVAX
NOVAVAX INC
SALE
10,420——0Jun 12, 2025Jun 13, 2025 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,476——14,476Jun 10, 2025Jun 12, 2025 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,689——1,689Jun 10, 2025Jun 12, 2025 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
62,728——62,728Jun 10, 2025Jun 12, 2025 ↗View →
NVAX
NOVAVAX INC
PURCHASE
6,670——43,920Jun 12, 2024Jun 13, 2024 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
15,630$15.86$247.9K15,630Jun 12, 2024Jun 13, 2024 ↗View →
NVAX
NOVAVAX INC
SALE
6,670——0Jun 12, 2024Jun 13, 2024 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
10,420——10,420Jun 12, 2024Jun 13, 2024 ↗View →
MXCT
MAXCYTE, INC.
PURCHASEGRANT
Stock grant
21,367——121,367Jun 11, 2024Jun 13, 2024 ↗View →
MXCT
MAXCYTE, INC.
PURCHASEGRANT
Stock grant
40,701——40,701Jun 11, 2024Jun 13, 2024 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,215——1,215Jun 4, 2024Jun 6, 2024 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
40,282——40,282Jun 4, 2024Jun 6, 2024 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,418——10,418Jun 4, 2024Jun 6, 2024 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,222——21,222Jun 30, 2023Jul 5, 2023 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
640——640Jun 30, 2023Jul 5, 2023 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,488——5,488Jun 30, 2023Jul 5, 2023 ↗View →
MXCT
MAXCYTE, INC.
PURCHASEGRANT
Stock grant
50,000——50,000Jun 22, 2023Jun 23, 2023 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
7,710——7,710Jun 12, 2023Jun 13, 2023 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
6,670——6,670Jun 12, 2023Jun 13, 2023 ↗View →
NVAX
NOVAVAX INC
SALE
3,100——0Jun 10, 2023Jun 13, 2023 ↗View →
NVAX
NOVAVAX INC
PURCHASE
3,100——37,250Jun 10, 2023Jun 13, 2023 ↗View →
MXCT
MAXCYTE, INC.
PURCHASE
80,000$4.32$345.5K100,000Mar 29, 2023Mar 30, 2023 ↗View →
MXCT
MAXCYTE, INC.
PURCHASEGRANT
Stock grant
26,900——26,900Jun 29, 2022Jul 8, 2022 ↗View →
NVAX
NOVAVAX INC
PURCHASE
700——34,150Jun 17, 2022Jun 21, 2022 ↗View →
NVAX
NOVAVAX INC
SALE
700——0Jun 17, 2022Jun 21, 2022 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
3,100——3,100Jun 10, 2022Jun 14, 2022 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
4,600——4,600Jun 10, 2022Jun 14, 2022 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
53,812——53,812Jun 7, 2022Jun 9, 2022 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,624——1,624Jun 7, 2022Jun 9, 2022 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,917——13,917Jun 7, 2022Jun 9, 2022 ↗View →
NVAX
NOVAVAX INC
PURCHASE
1,500$25.60$38.4K33,450Dec 13, 2021Dec 15, 2021 ↗View →
NVAX
NOVAVAX INC
SALE
1,500——0Dec 13, 2021Dec 15, 2021 ↗View →
MXCT
MAXCYTE, INC.
PURCHASE
20,000$11.12$222.4K20,000Nov 22, 2021Nov 23, 2021 ↗View →
MXCT
MAXCYTE, INC.
PURCHASEGRANT
Stock grant
10,000——10,000Aug 9, 2021Aug 11, 2021 ↗View →
NVAX
NOVAVAX INC
PURCHASE
3,450——31,950Jun 25, 2021Jun 29, 2021 ↗View →
NVAX
NOVAVAX INC
SALE
3,450——0Jun 25, 2021Jun 29, 2021 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
1,300——1,300Jun 17, 2021Jun 22, 2021 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
700——700Jun 17, 2021Jun 22, 2021 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,534——13,534Jun 8, 2021Jun 10, 2021 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
408——408Jun 8, 2021Jun 10, 2021 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,500——3,500Jun 8, 2021Jun 10, 2021 ↗View →
NVAX
NOVAVAX INC
PURCHASE
1,000$50.00$50.0K28,500Dec 31, 2020Jan 5, 2021 ↗View →
NVAX
NOVAVAX INC
SALE
1,000——0Dec 31, 2020Jan 5, 2021 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
6,900——6,900Jun 25, 2020Jun 26, 2020 ↗View →
NVAX
NOVAVAX INC
PURCHASEGRANT
Stock grant
3,450——3,450Jun 25, 2020Jun 26, 2020 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
26,503——26,503Jun 9, 2020Jun 11, 2020 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,079——1,079Jun 9, 2020Jun 11, 2020 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,245——9,245Jun 9, 2020Jun 11, 2020 ↗View →
ALDX
ALDEYRA THERAPEUTICS, INC.
PURCHASE
40,000$2.75$110.0K125,000Mar 16, 2020Mar 17, 2020 ↗View →
Other insiders · MXCT
Loading peer insiders…
About this filer
CIK 0001021015
ROLE
Director
PRIMARY
MXCT
COMPANIES
3
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001021015DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback